Compare Krispy Kreme Inc (DNUT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Recursion Pharmaceuticals Inc — how do they compare? Krispy Kreme Inc trades at $3 (market cap $521.37M), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.1× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DNUT | RXRX | |
|---|---|---|
Market Cap | $521.37M | $2.14B |
Volume | 2,293,015 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $6.79 |
52-Week Low | $2.87 | $2.84 |
Typical Hold Time | 45 Days | 22 Days |
Enterprise Value | $1.76B | $1.66B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $515.77M in 2025, with a negative net income margin of -33.88%, though revenue remains stable at $1.52B. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, alongside seasonal product launches like the Pokémon doughnut collection.
The outlook is mixed; analyst consensus leans buy (50%) with a low P/S of 0.34 offering value, but profitability challenges and legal overhangs pose significant risks. Cash flow improved in 2025, yet high debt and negative ROE of -14.43% demand caution for stock investors seeking turnaround potential amid competitive pressures.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
